SAN DIEGO, June 15, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that
Amit Munshi, the Company's President
and Chief Executive Officer, will present a corporate update at the
JMP Securities Life Sciences Conference on Wednesday, June 21, at 1:30 p.m. EDT. The conference will take place
June 20-21, 2017, at the St. Regis in
New York City.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
At Arena, we are focused
on developing novel, small molecule drugs with optimized receptor
pharmacology designed to deliver broad clinical utility across
multiple therapeutic areas. Our proprietary pipeline includes
potentially first- or best-in-class programs for which we own
global commercial rights. Our three most advanced
investigational clinical programs are ralinepag (APD811) in Phase 2
evaluation for pulmonary arterial hypertension (PAH), etrasimod
(APD334) in Phase 2 evaluation for multiple autoimmune indications
including ulcerative colitis (UC), and APD371 in Phase 2 evaluation
for the treatment of pain associated with Crohn's disease. In
addition, we have collaborations with the following pharmaceutical
companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage),
Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim
International GmbH (preclinical candidate).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the upcoming presentation; and Arena's focus, the
potential of its programs, and collaborations. For such statements,
Arena claims the protection of the Private Securities Litigation
Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results
to differ materially from the forward-looking statements include
those disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact
Kevin R. Lind
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-jmp-securities-life-sciences-conference-300474360.html
SOURCE Arena Pharmaceuticals, Inc.